A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung diseaseMasaki Hanibuchi, Yasuhiko Nishioka, Soji Kakiuchi et al.|Lung Cancer|2018Cited by 31
Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of JapanTakanori Kanematsu, Saburo Sone, Shoji Sakiyakma et al.|The Journal of Medical Investigation|2010Cited by 15
Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancerHisatsugu Goto, Yasuhiko Nishioka, Yoshio Okano et al.|Respiratory Investigation|2017Cited by 13
Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancerYuki Tsukazaki, Yasuhiko Nishioka, Hirokazu Ogino et al.|International Journal of Clinical Oncology|2024Cited by 8
Tepotinib-induced interstitial lung disease in a patient with adenosquamous lung carcinomaTakeshi Imakura, Takashi Haku, Soji Kakiuchi et al.|Respiratory Medicine Case Reports|2025Cited by 1